{'fraction_non_alphanumeric': 0.027602523659305992, 'fraction_numerical': 0.0015772870662460567, 'mean_word_length': 5.82258064516129, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Editorial: “Please Sir, I want some more” data to guide delivery of abdominopelvic radiotherapy in patients with inflammatory bowel disease

The Groupe d’Études Thérapeutiques des Affections Inflammatories Digestives (GETAID) has presented the largest, and only multicentre study of abdominopelvic radiotherapy in patients with inflammatory bowel disease (IBD).1 Data presented included patients treated in the era of intensity-modulated radiation therapy (IMRT), the greatest advancement in toxicity prevention seen in recent decades. Prior studies done before IMRT were commonplace, represented single institution data and were less applicable to contemporary practice.2 GETAID data suggest pelvic radiotherapy may not be as dangerous for IBD patients as implied by earlier studies. Nonetheless, analysis of data in this valuable manuscript leaves one asking, in the words of Oliver Twist, “Please Sir, I want some more.” Building on GETAID’s excellent start, cross-discipline collaborations will be critical. The greatest challenge is our collective, mutual need to learn the metrics and terms of colleagues across the gastroenterology-radiotherapy spectrum. Accordingly, I offer explanations of the unique ways in which radiation oncologists consider side effects.